Zevra Therapeutics
ZVRA
60 hedge funds and large institutions have $33.8M invested in Zevra Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 14 closing their positions.
213% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 8
26% more capital invested
Capital invested by funds: $26.9M → $33.8M (+$6.91M)
0.75% more ownership
Funds ownership: 17% → 17.75% (+0.75%)
7% less call options, than puts
Call options by funds: $2.32M | Put options by funds: $2.51M
13% less funds holding
Funds holding: 69 → 60 (-9)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.84M |
| 2 |
Jane Street
New York
|
+$809K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$374K |
| 4 |
Millennium Management
New York
|
+$337K |
| 5 |
Morgan Stanley
New York
|
+$200K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$411K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$321K |
| 3 |
Man Group
London,
United Kingdom
|
-$175K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$139K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$138K |
ZVRA Hedge Fund Activity: Q1 2023 in Review
60 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q1 2023, worth a combined $33.8M — up 26% from $26.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ZVRA and 6 opened new positions — a net loss of 8 holders — while 8 trimmed existing stakes and 25 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $1.84M. The largest seller was Citadel Advisors, cutting an estimated $411K.
- 60 institutional investors held Zevra Therapeutics (ZVRA) as of Q1 2023, down from 69 in Q4 2022.
- Funds reported $33.8M of Zevra Therapeutics stock for Q1 2023, up 26% quarter-over-quarter.
- 6 funds opened new Zevra Therapeutics positions in Q1 2023 and 14 closed out, a net change of -8 holders.
- The largest Zevra Therapeutics buyer in Q1 2023 was Great Point Partners, an estimated $1.84M added.
- The largest Zevra Therapeutics seller in Q1 2023 was Citadel Advisors, an estimated $411K sold.
Based on aggregated 13F filings for Q1 2023.